Initiation of new glucose-lowering therapies may act to reduce physical activity levels: pooled analysis from three randomized trials

OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS. We pooled data (n = 148) from three randomised trials to investiga...

Full description

Saved in:
Bibliographic Details
Main Authors: Tom Yates, Jack Sargeant, James King, Joe Henson, Charlotte Edwardson, Emma Redman, Gaurav Gulsin, Emer Brady, Ehtasham Ahmad, David Stensel, David Webb, Gerry McCann, Kamlesh Khunti, Melanie Davies
Format: Article
Language:English
Subjects:
Endocrinology & Metabolism
Medical and Health Sciences
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS. We pooled data (n = 148) from three randomised trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison to sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies on accelerometer-assessed physical activity. RESULTS: Liraglutide (-1144 steps/day; 95% CI -2069, -220), empagliflozin (-1132 steps/day; -1739, -524) and sitagliptin (-852 steps/day; -1625, -78) resulted in reduced total daily physical activity after 6 months (p< 0.01 vs. control). Moderate-to-vigorous intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity. CONCLUSIONS: The initiation of all glucose lowering therapies was associated with reduced physical activity, warranting further investigation.